Table 2.

Summary of Canadian cost-utility studies.

			Base Case Median Incremental Cost-Effectiveness Ratio ($/QALY*)
Publication Year	Reference	Vaccine Type	Societal Perspective	Payer Perspective	Study Conclusion
2002	25	Meningococcal	68,000	NR	Cost-effective‡
2004	26	Meningococcal	42,000	NR	Cost-effective
2005	27	Hepatitis C	D§	NR	Dominant
2007	28	Hepatitis A	NR†	D	Dominant
2007	29	HPV	NR	25,786	Probably Cost-effective‡
2007	30	Meningococcal	113,000	NR	Not Cost-effective
2008	31	Herpes Zoster	NR	33,000	Probably Cost-effective
2008	32	HPV	NR	1,249-3,291	Cost-effective
2009	33	Herpes Zoster	NR	41,709	Probably Cost-effective
2009	34	HPV	NR	27,398	Probably Cost-effective
2009	35	Pneumococcal	466	18,000	Cost-effective
2010	36	Influenza	NR	9,388	Cost-effective
2010	37	Influenza	NR	12,154	Cost-effective
2010	38	Pneumococcal	NR	D	Dominant
2011	39	Hepatitis B	NR	3,648,123	Not Cost-effective‡
2011	40	HPV	NR	1,839	Cost-effective
2011	41	Influenza	NR	1,612	Cost-effective
2011	42	Influenza	D	NR	Dominant
2011	43	Pertussis	NR	D	Dominant
2012	44	HPV	NR	D	Dominant
2012	45	Rotavirus	NR	2,400	Cost-effective
2012	46	Rotavirus	D	115,000	Dominant

^*QALY: Quality-adjusted Life Years

^†NR: Not reported

^§D: Dominant: The intervention costs less and is at least as effective as the comparator.

^‡Cost-effectiveness: defined by Canada's implicit threshold of $20,000/QALY – 100,000/QALY

Categories of cost-effectiveness:

^•Cost-effective – less than $20,000 CAD/QALY;

^•Probably cost-effective – between $20,000 CAD/QALY –$100,000 CAD/QALY;

^•Not cost-effective – greater than $100,000 CAD/QALY.